Transcript
Well, hello, everybody. Welcome to Monday, the S&P 500 was up today, almost three quarters of 1%, which is a good day. And all of our targeted indexes, and our two individual stocks did better than the S&P 500 today. So last Monday was one of the best days I have seen for our portfolios, since this recovery started back in mid March. And today was really good also. So it’s been great to see. And it really was led by semiconductors that were up 3.1%, our immunotherapy and Genomics targeting index that was up 2.8, and
Apple, which was up 2.4% today. So those are all great. It is interesting to look at what happened last week. So last week, the the categories that did the best buy order were banks, energy, homebuilders, retail, small cap, mid cap and emerging markets. All of those categories are relying upon a situation where the virus is under control, specifically through some type of a vaccine. There are four companies right now that are heading into stage three trials, there’s going to be 120,000 people trying out these vaccines. And we’ve heard some good news, we’ve heard some bad news.
We don’t know what works yet. It’s really fascinating. But the market is taking a look at these recovery stocks. And that’s the big tug of war that’s happening right now is kind of what’s going to happen between these is it going to be those stocks that do well during a virus situation, kind of like what we have, or those stocks that do well in a recovery situation. Now, the one part that I do like is the stocks that do well during the virus situation that we have now will also do well in a reopening situation. But at least temporarily and for a short period of time, you’re going to see a lot of money move towards those reopening stocks because they’re so cheap. And so that’ll be interesting to see how that plays out.
So so far today, it was really our our holding set did well. So let’s see what happens tomorrow as this battle continues. And I’ll talk to you then we’ll see what happens. Thank you.